CHA Biotech Co. Ltd Cash Flow Conversion Efficiency

Latest as of June 2026: 0.000x

CHA Biotech Co. Ltd cash flow conversion efficiency. Based on the latest financial reports, CHA Biotech Co. Ltd (085660) has a cash flow conversion efficiency ratio of 0.000x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (₩-208.26 Million ≈ $-141.14K USD) by net assets (₩1.03 Trillion ≈ $695.85 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Cash Flow Conversion Efficiency of CHA Biotech Co. Ltd (2009–2025)

Cash flow conversion efficiency of CHA Biotech Co. Ltd from 2009 to 2025. This chart illustrates how CHA Biotech Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. View current stock price of CHA Biotech Co. Ltd for real-time trading data and today's change.

CHA Biotech Co. Ltd Cash Flow Conversion Ratio Explained

CHA Biotech Co. Ltd cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.

CHA Biotech Co. Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of CHA Biotech Co. Ltd ranked by their cash flow conversion efficiency. Also see 085660 market cap for the company's overall valuation and market capitalisation.

Company Cash Flow Conversion Efficiency
Bannari Amman Sugars Limited
NSE:BANARISUG
0.130x
Daou Data Corp
KQ:032190
-0.181x
Napatech A/S
OL:NAPA
-0.214x
Trade-Van Information Services Co
TW:6183
0.038x
Sichuan Etrol Technologies Co Ltd
SHE:300370
0.014x
Kumyang
KO:001570
0.000x
Apex International Co Ltd
TW:4927
0.007x
Leo Lithium Ltd
AU:LLL
0.013x

Annual Cash Flow Conversion Efficiency for CHA Biotech Co. Ltd (2009–2025)

The table below shows the annual cash flow conversion efficiency of CHA Biotech Co. Ltd from 2009 to 2025. Review 085660 free cash flow generation to assess how much free cash flow the company generates relative to operating cash flow.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-12-31 ₩809.25 Billion
≈ $548.42 Million
₩-72.52 Billion
≈ $-49.15 Million
-0.090x +48.51%
2024-12-31 ₩284.69 Billion
≈ $192.93 Million
₩-49.55 Billion
≈ $-33.58 Million
-0.174x -1092.29%
2023-12-31 ₩656.33 Billion
≈ $444.79 Million
₩11.51 Billion
≈ $7.80 Million
0.018x +124.80%
2022-12-31 ₩291.73 Billion
≈ $197.70 Million
₩-20.63 Billion
≈ $-13.98 Million
-0.071x -245.08%
2021-12-31 ₩456.06 Billion
≈ $309.06 Million
₩22.23 Billion
≈ $15.06 Million
0.049x -63.17%
2020-12-31 ₩355.09 Billion
≈ $240.64 Million
₩47.00 Billion
≈ $31.85 Million
0.132x +97.78%
2019-12-31 ₩377.18 Billion
≈ $255.61 Million
₩25.24 Billion
≈ $17.10 Million
0.067x -70.97%
2018-12-31 ₩326.99 Billion
≈ $221.60 Million
₩75.38 Billion
≈ $51.09 Million
0.231x +342.94%
2017-12-31 ₩230.74 Billion
≈ $156.37 Million
₩12.01 Billion
≈ $8.14 Million
0.052x +31.95%
2016-12-31 ₩286.32 Billion
≈ $194.04 Million
₩11.29 Billion
≈ $7.65 Million
0.039x -81.50%
2015-12-31 ₩290.10 Billion
≈ $196.60 Million
₩61.86 Billion
≈ $41.92 Million
0.213x +3732.73%
2014-12-31 ₩437.45 Billion
≈ $296.46 Million
₩-2.57 Billion
≈ $-1.74 Million
-0.006x -104.53%
2013-12-31 ₩512.34 Billion
≈ $347.21 Million
₩66.35 Billion
≈ $44.97 Million
0.130x -6.23%
2012-12-31 ₩331.41 Billion
≈ $224.59 Million
₩45.77 Billion
≈ $31.02 Million
0.138x +13.63%
2011-12-31 ₩285.46 Billion
≈ $193.45 Million
₩34.69 Billion
≈ $23.51 Million
0.122x -54.29%
2010-12-31 ₩158.24 Billion
≈ $107.24 Million
₩42.07 Billion
≈ $28.51 Million
0.266x +39.05%
2009-12-31 ₩125.61 Billion
≈ $85.12 Million
₩24.02 Billion
≈ $16.28 Million
0.191x --

About CHA Biotech Co. Ltd

KQ:085660 Korea Biotechnology
Market Cap
$428.43 Million
₩632.19 Billion KRW
Market Cap Rank
#12736 Global
#360 in Korea
Share Price
₩6800.00
Change (1 day)
+0.74%
52-Week Range
₩6750.00 - ₩23850.00
All Time High
₩40950.00
About

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising f… Read more